⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Post-market surveillanceThyroid Analog

Compound 61653

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061653
Risk Class
MODERATE
Last Audit
May 26, 2108

Research Abstract

Thyroid Analog candidate engineered for oncology adjuvant initiatives with automated dossier coverage.

Compound 61653 is a thyroid analog asset inside thyroid analog innovation track initiatives, optimized for oncology adjuvant and inflammation control.

The dossier currently sits in post-market surveillance with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061653 with updates logged 2108-05-26.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Oncology adjuvantInflammation control

Nomenclature

CX-61653Thyroid Analog Program 61653

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061653
  2. [2] Operations Pulse • Thyroid Analog innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61653